Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease
- PMID: 12835121
- DOI: 10.1007/BF03033137
Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease
Abstract
Dopamine (DA)- or L-dihydroxyphenylalanine-(L-DOPA-) induced neurotoxicity is thought to be involved not only in adverse reactions induced by long-term L-DOPA therapy but also in the pathogenesis of Parkinson's disease. Numerous in vitro and in vivo studies concerning DA- or L-DOPA-induced neurotoxicity have been reported in recent decades. The reactive oxygen or nitrogen species generated in the enzymatical oxidation or auto-oxidation of an excess amount of DA induce neuronal damage and/or apoptotic or non-apoptotic cell death; the DA-induced damage is prevented by various intrinsic and extrinsic antioxidants. DA and its metabolites containing two hydroxyl residues exert cytotoxicity in dopaminergic neuronal cells mainly due to the generation of highly reactive DA and DOPA quinones which are dopaminergic neuron-specific cytotoxic molecules. DA and DOPA quinones may irreversibly alter protein function through the formation of 5-cysteinyl-catechols on the proteins. For example, the formation of DA quinone-alpha-synuclein consequently increases cytotoxic protofibrils and the covalent modification of tyrosine hydroxylase by DA quinones. The melanin-synthetic enzyme tyrosinase in the brain may rapidly oxidize excess amounts of cytosolic DA and L-DOPA, thereby preventing slowly progressive cell damage by auto-oxidation of DA, thus maintainng DA levels. Since tyrosinase also possesses catecholamine-synthesizing activity in the absence of tyrosine hydroxylase (TH), the double-edged synthesizing and oxidizing functions of tyrosinase in the dopaminergic system suggest its potential for application in the synthesis of DA, instead of TH in the degeneration of dopaminergic neurons, and in the normalization of abnormal DA turnover in the long-term L-DOPA-treated Parkinson's disease patients.
Similar articles
-
Dopaminergic neuron-specific oxidative stress caused by dopamine itself.Acta Med Okayama. 2008 Jun;62(3):141-50. doi: 10.18926/AMO/30942. Acta Med Okayama. 2008. PMID: 18596830 Review.
-
Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson's disease.Int J Mol Sci. 2010 Mar 12;11(3):1082-9. doi: 10.3390/ijms11031082. Int J Mol Sci. 2010. PMID: 20480001 Free PMC article. Review.
-
[Mechanism of specific dopaminergic neuronal death in Parkinson's disease].Nihon Rinsho. 2004 Sep;62(9):1629-34. Nihon Rinsho. 2004. PMID: 15462376 Review. Japanese.
-
Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.Neurosci Res. 2008 Jan;60(1):106-13. doi: 10.1016/j.neures.2007.10.002. Epub 2007 Oct 10. Neurosci Res. 2008. PMID: 18022268
-
l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.J Neurochem. 2019 Jul;150(1):88-106. doi: 10.1111/jnc.14676. Epub 2019 Mar 28. J Neurochem. 2019. PMID: 30716176
Cited by
-
D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II.Pharmaceutics. 2022 Sep 23;14(10):2018. doi: 10.3390/pharmaceutics14102018. Pharmaceutics. 2022. PMID: 36297453 Free PMC article.
-
L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.J Neurol. 2005 Oct;252 Suppl 4:IV23-IV31. doi: 10.1007/s00415-005-4006-7. J Neurol. 2005. PMID: 16222434 Review.
-
Dopamine, Immunity, and Disease.Pharmacol Rev. 2023 Jan;75(1):62-158. doi: 10.1124/pharmrev.122.000618. Epub 2022 Dec 8. Pharmacol Rev. 2023. PMID: 36757901 Free PMC article. Review.
-
Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture.J Neural Transm (Vienna). 2006 Sep;113(9):1107-18. doi: 10.1007/s00702-005-0369-2. Epub 2005 Oct 27. J Neural Transm (Vienna). 2006. PMID: 16252065
-
Proteome-Wide Profiling of Cellular Targets Modified by Dopamine Metabolites Using a Bio-Orthogonally Functionalized Catecholamine.ACS Chem Biol. 2021 Nov 19;16(11):2581-2594. doi: 10.1021/acschembio.1c00629. Epub 2021 Nov 2. ACS Chem Biol. 2021. PMID: 34726906 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases